SCHEMBL21286522

SCHEMBL21286522

CC(C)c1cc(Cc2c(Cl)cc(OCC(=O)NCCc3ccc(O)c(O)c3)cc2Cl)ccc1O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 11/20 0.68
THRB P10828 11/20 0.68
MAPT P10636 3/20 0.43
HSD17B10 Q99714 2/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
PTGS1 P23219 1/20 0.43
BLM P54132 1/20 0.43
HIF1A Q16665 1/20 0.43
ERCC1 P07992 1/20 0.43
ERCC4 Q92889 1/20 0.43
TRPV1 Q8NER1 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ALOX12 P18054 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CNR1 P21554 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21286516 0.94 THRA (0.60) THRATHRBMAPTHSD17B10KDM4E
SCHEMBL21286529 0.91 THRA (0.70) THRATHRBLMNAHPGDCA1
SCHEMBL19859404 0.89 THRB (0.67) THRATHRB
SCHEMBL21286638 0.89 THRB (0.72) THRATHRBALDH1A1
SCHEMBL21286552 0.89 THRB (0.72) THRATHRB
SCHEMBL21286523 0.89 THRA (0.68) THRATHRBMAPTHSD17B10KDM4E
SCHEMBL21286594 0.88 THRB (0.70) THRATHRB
SCHEMBL21286535 0.88 THRB (0.70) THRATHRB
SCHEMBL21286550 0.87 THRB (0.74) THRATHRBHPGD
SCHEMBL24632157 0.86 THRB (0.68) THRATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11578032-B2 Derivatives of sobetirome OREGON HEALTH & SCIENCE UNIVERSITY (US) 2023-02-14 US disclosed
WO-2022236133-A1 FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF THYROMIMETICS AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS AUTOBAHN THERAPEUTICS, INC. (US) 2022-11-10 WO disclosed
US-20210002208-A1 DERIVATIVES OF SOBETIROME OREGON HEALTH & SCIENCE UNIVERSITY (US) 2021-01-07 US disclosed
WO-2019160980-A1 DERIVATIVES OF SOBETIROME OREGON HEALTH & SCIENCE UNIVERSITY (US) 2019-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210002208-A1 DERIVATIVES OF SOBETIROME SLC6A3, TPH1, SLC6A2 THRA 213/4885THRB 149/4885MAPT 121/4885
US-11578032-B2 Derivatives of sobetirome SLC6A3, TPH1, SLC6A2 THRA 213/4885THRB 149/4885MAPT 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.